These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35174182)
1. Publication Trends of Research on Polypoidal Choroidal Vasculopathy During 2001-2020: A 20-Year Bibliometric Study. Wang Y; Xie M; Zhang M; Zhao X; Zhu X; Wang Y; Chen Y; Chen J; Sun X Front Med (Lausanne); 2021; 8():785126. PubMed ID: 35174182 [TBL] [Abstract][Full Text] [Related]
2. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy. Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169 [TBL] [Abstract][Full Text] [Related]
3. Differentiating Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy Using OCT B-Scan. Kokame GT; Omizo JN; Kokame KA; Yamane ML Ophthalmol Retina; 2021 Oct; 5(10):954-961. PubMed ID: 34022443 [TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy for polypoidal choroidal vasculopathy. Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257 [TBL] [Abstract][Full Text] [Related]
5. [Age-related Macular Degeneration in the Japanese]. Yoshimura N Nippon Ganka Gakkai Zasshi; 2016 Mar; 120(3):163-88; discussion 189. PubMed ID: 27164756 [TBL] [Abstract][Full Text] [Related]
6. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619 [TBL] [Abstract][Full Text] [Related]
8. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Gomi F; Ohji M; Sayanagi K; Sawa M; Sakaguchi H; Oshima Y; Ikuno Y; Tano Y Ophthalmology; 2008 Jan; 115(1):141-6. PubMed ID: 17582498 [TBL] [Abstract][Full Text] [Related]
15. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. Teo KYC; Gillies M; Fraser-Bell S Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632 [TBL] [Abstract][Full Text] [Related]
16. Polypoidal choroidal vasculopathy: an update on therapeutic approaches. Wong RL; Lai TY J Ophthalmic Vis Res; 2013 Oct; 8(4):359-71. PubMed ID: 24653824 [TBL] [Abstract][Full Text] [Related]
17. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Tong JP; Chan WM; Liu DT; Lai TY; Choy KW; Pang CP; Lam DS Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490 [TBL] [Abstract][Full Text] [Related]
18. Current management strategy of polypoidal choroidal vasculopathy. Ho CPS; Lai TYY Indian J Ophthalmol; 2018 Dec; 66(12):1727-1735. PubMed ID: 30451173 [TBL] [Abstract][Full Text] [Related]
19. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]